Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$38.73+0.02 (+0.05%)
Close on Nov 18, 2026Market cap $27.98BP/E –Yield –
Roivant Sciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Roivant Sciences's revenue for the twelve months ending Jun 30, 2026 was $7.53M, down 67.6% year over year. For fiscal 2025 it was $8.26M, down 71.6% from the year before. The highest annual figure on record is $55.29M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2026 | $8.26M | -71.6% |
| FY2024 | Mar 31, 2025 | $29.05M | -11.2% |
| FY2023 | Mar 31, 2024 | $32.71M | +3.8% |
| FY2022 | Mar 31, 2023 | $31.53M | -43.0% |
| FY2021 | Mar 31, 2022 | $55.29M | +132.3% |
| FY2020 | Mar 31, 2021 | $23.80M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ2 2026 | Jun 30, 2026 | $1.44M | -33.5% |
| Q4 FY2025CQ1 2026 | Mar 31, 2026 | $2.52M | -66.7% |
| Q3 FY2025CQ4 2025 | Dec 31, 2025 | $2.00M | -77.8% |
| Q2 FY2025CQ3 2025 | Sep 30, 2025 | $1.57M | -64.9% |
| Q1 FY2025CQ2 2025 | Jun 30, 2025 | $2.17M | -72.8% |
| Q4 FY2024CQ1 2025 | Mar 31, 2025 | $7.57M | -16.1% |
| Q3 FY2024CQ4 2024 | Dec 31, 2024 | $9.02M | -42.1% |
| Q2 FY2024CQ3 2024 | Sep 30, 2024 | $4.48M | +22.7% |
| Q1 FY2024CQ2 2024 | Jun 30, 2024 | $7.99M | -63.1% |
| Q4 FY2023CQ1 2024 | Mar 31, 2024 | $9.02M | -67.1% |
| Q3 FY2023CQ4 2023 | Dec 31, 2023 | $15.56M | -8.7% |
| Q2 FY2023CQ3 2023 | Sep 30, 2023 | $3.65M | -70.9% |
| Q1 FY2023CQ2 2023 | Jun 30, 2023 | $21.62M | +400.7% |
| Q4 FY2022CQ1 2023 | Mar 31, 2023 | $27.38M | +196.8% |
| Q3 FY2022CQ4 2022 | Dec 31, 2022 | $17.05M | -29.9% |
| Q2 FY2022CQ3 2022 | Sep 30, 2022 | $12.53M | -10.4% |
| Q1 FY2022CQ2 2022 | Jun 30, 2022 | $4.32M | -44.2% |
| Q4 FY2021CQ1 2022 | Mar 31, 2022 | $9.22M | -39.1% |
| Q3 FY2021CQ4 2021 | Dec 31, 2021 | $24.34M | +323.3% |
| Q2 FY2021CQ3 2021 | Sep 30, 2021 | $13.99M | +957.2% |
| Q1 FY2021CQ2 2021 | Jun 30, 2021 | $7.74M | +390.8% |
| Q4 FY2020CQ1 2021 | Mar 31, 2021 | $15.15M | – |
| Q3 FY2020CQ4 2020 | Dec 31, 2020 | $5.75M | – |
| Q2 FY2020CQ3 2020 | Sep 30, 2020 | $1.32M | – |
| Q1 FY2020CQ2 2020 | Jun 30, 2020 | $1.58M | – |
See a number that looks wrong?